مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

1,941
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

0
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

EVALUATION OF JAK2 V617F MUTATION AND CORRELATIONS OF THIS MUTATION WITH CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Pages

  1-11

Abstract

 Background: In 2005, multiple groups identified a high frequency of the V617F (G®T) mutation in the tyrosine kinase gene JAK2 in MYELOPROLIFERATIVE NEOPLASMS. In this study, we evaluated prevalence of JAK2 mutation and it’s clinical and laboratory correlates in patients with MYELOPROLIFERATIVE NEOPLASMS (MPNs). Methods: The JAK2 mutation was investigated with ARMS-PCR in 92 patients with MYELOPROLIFERATIVE NEOPLASMS by simple randomized sampling.Findings: The JAK2 V617F MUTATION was detected in 86.6% (26/30) of patients with polycythemia vera, 46.6% (7/15) of patients with essential thrombocythemia, 61.5% (8/13) of patients with idiopathic myelofibrosis, and 14% (4/34) of patients with chronic myeloid leukemia. Polycythemia vera patients carrying the mutation displayed a higher levels of WBC (P = 0.03); 61.5% (16/26) of these patients were female and 17 patients had splenomegaly. One patient had simultaneously JAK2 V617F MUTATION and Philadelphia chromosome. The differences in other groups were not significant. The mutation was confirmed by sequencing. Conclusion: These correlations imply that detection of this mutation will not only have a diagnostic value, but also a role in treatment given the development of STAT/JAK pathway inhibiting drugs.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    NADALI, FATEMEH, FERDOUSI, SH., EYN ELAHI, N., MOUSAVI, S.A.A., CHAHARDOULI, B., TOUGHEH, GH.R., ALI MOGHADAM, K., GHAVAMZADEH, ARDESHIR, & GHAFARI, S.H.A.. (2010). EVALUATION OF JAK2 V617F MUTATION AND CORRELATIONS OF THIS MUTATION WITH CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), 28(105), 1-11. SID. https://sid.ir/paper/356915/en

    Vancouver: Copy

    NADALI FATEMEH, FERDOUSI SH., EYN ELAHI N., MOUSAVI S.A.A., CHAHARDOULI B., TOUGHEH GH.R., ALI MOGHADAM K., GHAVAMZADEH ARDESHIR, GHAFARI S.H.A.. EVALUATION OF JAK2 V617F MUTATION AND CORRELATIONS OF THIS MUTATION WITH CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S)[Internet]. 2010;28(105):1-11. Available from: https://sid.ir/paper/356915/en

    IEEE: Copy

    FATEMEH NADALI, SH. FERDOUSI, N. EYN ELAHI, S.A.A. MOUSAVI, B. CHAHARDOULI, GH.R. TOUGHEH, K. ALI MOGHADAM, ARDESHIR GHAVAMZADEH, and S.H.A. GHAFARI, “EVALUATION OF JAK2 V617F MUTATION AND CORRELATIONS OF THIS MUTATION WITH CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS,” JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), vol. 28, no. 105, pp. 1–11, 2010, [Online]. Available: https://sid.ir/paper/356915/en

    Related Journal Papers

    Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top